AI-powered Lunit INSIGHT CXR and Lunit INSIGHT MMG to enhance lung and breast cancer detection in Taiwan and Singapore
SEOUL, South Korea, March 11, 2024 -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region. Lunit will supply its Lunit INSIGHT CXR for chest abnormality detection and Lunit INSIGHT MMG for mammography analysis to the Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore, respectively.
Chung Shan Medical University to Pioneer AI in Lung Cancer Detection
Under the newly inked supply contract, Lunit will collaborate with the prestigious Chung Shan Medical University (CSMU), Taiwan's leading medical university. This collaboration holds the potential to revolutionize Taiwan's national lung cancer screening program.
Compared to Taiwan’s current screening program, which relies on low‐dose computed tomography (LDCT) for screening high-risk individuals such as smokers or those with a family history of lung cancer, CSMU aims to validate Lunit INSIGHT CXR for potential integration into the national cancer screening program. The goal is to assess its ability to detect individuals more accurately and efficiently, potentially expanding the screening to a broader group beyond high-risk individuals. This approach could significantly advance Taiwan's efforts to enhance early detection and improve outcomes in lung cancer screening.
At a glance
- Company
- Lunit
- Ticker
- KRX: 328130.KQ
- Announcement
- Partnership
- Location
- Taiwan and Singapore
Key figures
- Gleneagles Hospital Singapore beds
- 221 beds
People
- Brandon SuhCEO of Lunit
Products and programs
Gleneagles Hospital Singapore Chooses Lunit for Enhanced Breast Cancer Screening
In a parallel move, Lunit is set to deliver its AI-powered mammography analysis solution, Lunit INSIGHT MMG, to Gleneagles Hospital in Singapore, a prominent private healthcare facility within the IHH group. Gleneagles plans to enhance screening accuracy and operational efficiency by seamlessly integrating Lunit's cutting-edge technology into its breast screening workflow.
Gleneagles Hospital, part of Southeast Asia's largest medical group, IHH, is a leading private healthcare provider in the region. Recognized with the Singapore Quality Class certification, the hospital offers extensive clinical facilities with 221 beds, emphasizing its commitment to exceptional standards in healthcare.
"As demand for cutting-edge medical services continues to rise across East and Southeast Asia, Lunit is proud to spearhead the advancement of AI-powered solutions for cancer diagnostics in the region,” said Brandon Suh, CEO of Lunit. “Our strategic partnerships with Chung Shan Medical University and Gleneagles Hospital Singapore strengthen our presence and open new opportunities across the market. We believe that these contracts will pave the way for innovative approaches to cancer detection, ultimately improving patient outcomes in areas where they are most crucial."
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
In brief
Lunit says it has signed two supply contracts to bring its AI medical imaging products to healthcare providers in Taiwan and Singapore. Chung Shan Medical University will receive Lunit INSIGHT CXR for chest abnormality detection and plans to evaluate its potential role in Taiwan’s lung cancer screening program. The university aims to assess whether the tool could support screening beyond people currently considered high-risk. Separately, Gleneagles Hospital Singapore will use Lunit INSIGHT MMG for mammography analysis, with the stated aim of improving screening accuracy and workflow efficiency. Lunit CEO Brandon Suh said the agreements expand the company’s regional presence and could support new cancer detection approaches. The release does not state contract values or timelines for implementation.
Key takeaways
- Lunit signed supply agreements with Chung Shan Medical University in Taiwan and Gleneagles Hospital Singapore.
- The Taiwan contract covers Lunit INSIGHT CXR for evaluation in lung cancer screening.
- Gleneagles Hospital Singapore plans to integrate Lunit INSIGHT MMG into its breast screening workflow.
- Lunit CEO Brandon Suh said the agreements expand the company’s presence in East and Southeast Asia.
Earlier from Lunit
- Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings
- New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC
- Lunit INSIGHT CXR Excels in Long Nodule Detection - Exceptional Performance in Head-to-Head Study published in Radiology
- Lunit AI Solutions to Power Samsung's X-ray Devices for Advanced Chest Screening
- Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
